Vaccines work by educating the immune system about the tumor’s identity, but it can be challenging to deliver that “intel” to the proper cells that can act upon it. To address that, Dr. Lajoie is using nanoparticles to improve our ability to deliver that information successfully. His system is unique in that the nanoparticles are made from self-assembling proteins, which allows their structure to be encoded in DNA or RNA. This also makes it easy to make modifications and tailor the nanoparticle properties to ensure that their inner payload is delivered to the right place within the right cells. After validating the approach in cells, Dr. Lajoie will test the approach in mice. If successful, the hope is that it could then be used to improve survival in human patients.
University of Washington | All Cancers | 2016 | David A. Baker, Ph.D.
Marc J. Lajoie et al | Science | 2022 | DOI
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
This Skin Cancer Awareness month, discover new research, treatments, and progress for a future immune to skin cancer.
Birdies & Brews mixes beer and golf while raising funds for cancer immunotherapy research.